he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:哪些抗菌类固醇可诱发癫痫?
下一页:哪些抗菌药物可归因于癫痫?
- 2022-05-022013年国际抗癫痫协会抗癫痫药使用指南
- 2022-04-25发作患儿死亡简析
- 2022-04-25癫痫患儿生还简析
- 2022-04-13癫痫发作对中风患者静脉溶栓的长期转移有效
- 2022-04-12英国竞争监管机构指控辉瑞癫痫药品价格过高
- 2022-04-11癫痫猝死:凶手是谁?
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 癫痫猝死:凶手是谁?
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 癫痫治愈费用
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- FDA批准Aptiom用于治疗患者癫痫发作
- 抗癫痫药物预防新发癫痫:任重而道远
- 预测癫痫患者再入院风险
- 罕见病例:自发性颞极性扩张伴癫痫发作
- 北京癫痫医院治疗费用
- 脑梗死的症状是什么有这些前兆要谨慎
- 上海率先探索异地就医门诊费直接结算
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 北京癫痫手术费用
- 癫痫患者手术评估新型工具
- 2016AAN:神经专家发表了有前途的专业见解
- Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 2013国际抗癫痫联合会抗癫痫药用指南
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 老年人癫痫的症状是什么?
- 三庚酸酯可治疗1型转运体缺陷综合征
- 成人羊角风病的病因是什么?
- 癫痫症状 如何护理癫痫患者?
- 癫痫治疗障碍仍难以克服
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 2015 神经系统疾病诊疗进展
- 先天性癫痫病有什么病症
- 大脑缺氧 大脑缺氧的副作用
- 什么是难治性帕金森氏症?手术办法及适应症
- 治疗癫痫病很好的方法是什么
- 天气越来越冷 癫痫患者防范病情有妙招
- 癫痫病的病症有什么-
- 为啥狗狗睡觉时抽搐,是身体有问题还是在心里,文章为你解答!
- 用药隐源性癫痫病要多少钱
- 樟脑丸成分 樟脑丸有哪些清热
- 癫痫病人的烹饪和生活有哪些需要注意的
- 大庆西部干细胞研究院:干细胞治疗脑出血后遗症国内有新药了!
- 怎么用科学的方式治疗癫痫病
- 癫痫发作的症状及急救控制措施
- 癫痫病的常见病因有哪些